Furthermore, melanoma‐related studies have revealed that OV therapy possesses dual immunomodulatory effects: inducing T cell infiltration into the TME while simultaneously inhibiting PD‐L1‐mediated negative immune regulation. This evidence concerns the gene CD274 and melanoma.